MedAdvisor Limited (ASX:MDR) Provides Strategic Review Update
MedAdvisor Limited (ASX:MDR) announces a strategic review update, detailing a potential $35 million sale of its ANZ business division to a major software firm.
Category: Healthcare
Orthocell Limited (ASX:OCC) Accelerates US Remplir™ Sales Rollout with 12 Distributors
Orthocell Limited (ASX:OCC) accelerates Remplir™ sales rollout with 12 US distributors, surpassing targets and setting the stage for first sales.
Acrux Limited (ASX:ACR) Launches Dapsone 7.5% Gel in the United States
Acrux Limited (ASX:ACR) launches its differentiated Dapsone 7.5% Gel in the US, enhancing its prescription acne treatment portfolio.
LTR Pharma Limited (ASX:LTP) Signs Collaborative Agreement for OROFLOW® Development
LTR Pharma (ASX:LTP) collaborates with SDS to develop OROFLOW®, a novel intranasal spray for Oesophageal Motility Disorders.
Algorae Pharmaceuticals (ASX:1AI) Partners with Peter MacCallum Cancer Centre for AI-Driven Drug Screening
Algorae Pharmaceuticals (ASX:1AI) partners with Peter MacCallum Cancer Centre to validate AI-driven drug synergies in oncology.
Pro Medicus Limited (ASX:PME) Signs A$20M Contract with University of Iowa Health Care
Pro Medicus Limited (ASX:PME) signs a A$20M, 5-year contract with University of Iowa Health Care for its cloud-based Visage 7 platform.
Nyrada Inc. (ASX:NYR) Announces Positive Preclinical Study Results for NYR-BI03
Nyrada Inc. (ASX:NYR) reports significant cardioprotective findings for NYR-BI03 in preclinical studies, demonstrating potential for treating heart attack-related conditions.
Echo IQ Limited (ASX:EIQ) Raises $17.3 Million via Institutional Placement
Echo IQ Limited (ASX:EIQ) raises A$17.3 million in an institutional placement to advance US market initiatives and technology development.
MedAdvisor Limited (ASX:MDR) Receives LOI for ANZ Division Acquisition
MedAdvisor Limited (ASX:MDR) receives a non-binding LOI to sell its ANZ division, reflecting a higher value than current share price.
CLINUVEL (ASX:CUV) Completes Phase III Vitiligo Trial Recruitment
CLINUVEL (ASX:CUV) completes recruitment for its Phase III vitiligo trial, with initial results expected in the second half of 2026.